Zentalis Pharmaceuticals (ZNTL) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 16, 2026, with virtual participation available to shareholders.

• Shareholders are encouraged to review proxy materials and vote by June 15, 2026.

Voting matters and shareholder proposals

• Election of two Class III Directors, David Johnson and Jan Skvarka, Ph.D., to serve until the 2029 annual meeting.

• Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.

• Advisory vote on executive compensation for named executive officers.

• Board recommends voting in favor of all proposals.

Board of directors and corporate governance

• Board nominees for Class III Directors are presented for election, with terms expiring in 2029.